| Date | Time | Source | Headline | Symbol | Company |
| 05/02/2024 | 2:07PM | iHub Newswire | FeaturedNanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon | | |
| 03/19/2024 | 9:00AM | GlobeNewswire Inc. | Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 03/06/2024 | 5:00PM | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 02/20/2024 | 8:42AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 02/20/2024 | 8:30AM | PR Newswire (US) | Oramed Letter to Shareholders | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 01/30/2024 | 5:30PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 01/23/2024 | 4:45PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 01/19/2024 | 4:45PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 01/08/2024 | 4:43PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 01/08/2024 | 4:41PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 01/08/2024 | 4:40PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 01/08/2024 | 4:39PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 01/08/2024 | 4:37PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 01/08/2024 | 4:37PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 01/08/2024 | 4:36PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 01/08/2024 | 4:36PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 01/08/2024 | 4:34PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 01/08/2024 | 4:33PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 01/08/2024 | 4:32PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 01/02/2024 | 1:13PM | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 12/21/2023 | 9:26AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 12/18/2023 | 4:45PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 11/09/2023 | 5:10PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 09/26/2023 | 4:34PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 09/22/2023 | 11:38AM | PR Newswire (US) | Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 09/21/2023 | 6:11PM | PR Newswire (US) | Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 09/21/2023 | 4:05PM | GlobeNewswire Inc. | Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc. | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 09/13/2023 | 9:00AM | GlobeNewswire Inc. | Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 09/13/2023 | 8:47AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |
| 08/10/2023 | 5:00PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ORMP | Oramed Pharmaceuticals Inc |